Intracardiac thrombus formation after the Fontan operation  by Balling, Gunter et al.
The aim of our study was to evaluate the occurrence
of intracardiac thrombi and to identify predisposing risk
factors to optimize diagnostic and therapeutic strategies
for patients after the Fontan operation.
Because of the unexpected high occurrence of intra-
cardiac thrombosis in this study, we decided to publish
these preliminary data, which are in everyone’s interest.
Patients and methods
Between 1978 and 1998, 227 patients with different types
of univentricular hearts underwent a modified Fontan opera-
tion at our institution, and 169 of them were routinely fol-
lowed up. Since January 1998, we initiated a study to evalu-
ate the occurrence of intracardiac thrombi in all these patients
visiting our outpatient clinic. Through June 1, 1999, the study
included 52 patients consecutively visiting our outpatient clin-
ic (24 female and 28 male patients), who were free of symp-
toms for thromboembolism or other clinical signs of hemody-
namic deterioration and could be motivated to participate in
the study. Informed consent was obtained for all participants.
Follow-up data were obtained by reviewing each patient’s
medical records. Besides a thorough physical examination,
the medical examinations consisted of electrocardiography,
24-hour ambulatory electrocardiography, transthoracic and
transesophageal echocardiography (TEE), cardiac catheteri-
zation, and laboratory testing.
The preoperative diagnosis included various forms of tri-
cuspid atresia in 23 patients, double-inlet left ventricle in 21,
mitral atresia in 4, and a complex type of a univentricular
heart in 4 (Table I).
S ince 1968, the original Fontan operation has under-gone several surgical modifications. It has been
applied for palliation of a wide variety of complex
cyanotic congenital heart defects with only one ventri-
cle precluding biventricular repair.1 Despite the signifi-
cant progress in operative management, considerable
late mortality and morbidity remain, mainly caused by
atrial arrhythmias, liver dysfunction, protein-losing
enteropathy, ventricular failure, thrombus formation,
and thromboembolic events.2-5
The true incidence of cardiac thrombi and throm-
boembolic events is unknown. Moreover, no consensus
is found in the literature regarding the tools for diagno-
sis of cardiac thrombi and the indication and optimal
strategy preventing thromboembolism.6
Objectives: Intracardiac thrombus formation is suspected to be a specific
sequela after the Fontan operation and is difficult to determine by means of
routine transthoracic echocardiography. The aim of our study was to evalu-
ate the occurrence of intracardiac thrombi in the different types of Fontan
modifications and to identify predisposing risk factors.
Methods: We evaluated 52 patients who had undergone a Fontan-type oper-
ation and were free of symptoms regarding thrombosis as determined by
transesophageal echocardiography.
Results: In 17 (33%) patients thrombus formation could be found without
clinical evidence of thromboembolic complications. Neither underlying
morphologic disease nor age at operation, type of Fontan operation, sex, fol-
low-up interval, arrhythmias, or laboratory or hemodynamic findings could
be identified as predisposing risk factors.
Conclusion: In patients having had a Fontan operation with inadequate or
without anticoagulation medication, we would recommend routine trans-
esophageal echocardiography to exclude eventual thrombi. Because of the
high incidence of thrombi, we suggest oral anticoagulation therapy in all
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INTRACARDIAC THROMBUS FORMATION AFTER THE FONTAN OPERATION
Preceding the definitive Fontan operation, 41 patients had
undergone different forms of palliation. The Fontan proce-
dure was performed as a direct atrial-pulmonary anastomosis
in 23 patients, an atrial–right ventricle connection (Fontan-
Björk modification) in 19 patients, and a total intracardiac
cavapulmonary connection (TCPC) in 10 patients. Included
are two patients who had conversion to a TCPC 8 years after
a primary Fontan-Björk connection.
The laboratory protocol included measurements of hemato-
logic parameters (red blood cell count and hematocrit level),
serum protein, albumin, and renal and liver function parame-
ters (serum alkaline phosphatase, gamma-glutamyl trans-
ferase, alanine transaminase, aspartate transaminase, and
total bilirubin), as well as the coagulation status (prothrombin
time, international normalized ratio [INR], fibrinogen,
antithrombin III, activated partial thromboplastin time, pro-
tein C, and protein S). All laboratory tests were done at the
same time as TEE evaluation.
The transthoracic echocardiography, including cross-sec-
tional view, pulse wave and continuous wave Doppler scan-
ning, and color flow mapping, was evaluated by two experi-
enced investigators with a Vingmed ultrasonographic system
(GE Vingmed Ultrasound AS; Strandpromenaden, Horten,
Norway) by using a 5.0-, 3.5-, or 2.5-MHz phased-array
transducer. The TEE study was performed after achievement
of local anesthesia in 27 patients and after achievement of
general anesthesia and intubation in the remaining 25
patients. A Vingmed 7.5-MHz mechanical multiplane pedi-
atric probe was used for all examinations with local anesthe-
sia, and a Vingmed 5-MHz mechanical multiplane adult
probe was used for those with general anesthesia. All exami-
nations were done by the same physician, and all tapes were
reviewed independently by another experienced investigator
blinded for the initial outcome.
A thrombus was defined as any localized echogenic mass
within the lumen of the left or right atrium or any other
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Table I. Patients, diagnosis, and thrombus
Patient Operation Age at Fontan Fontan Age at 
No. Sex Diagnosis before Fontan operation modification TEE Thrombus 
1 F MA, CA, MGA, levocardia PAB 7.1 Modified RA-RV 16.0 Thrombus
2 F DILV, MGA, PS PAB 9.5 RA-PA 18.2 Thrombus
3 F TA IIc, MGA PAB 6.3 RA-PA 14.9
4 M DILV, PS, MGA 11.7 RA-PA 25.6
5 F DILV, PS, MGA 5.8 RA-PA 16.5 Thrombus
6 F DILV, PA, hypoplastic LPA 2 × shunt 6.8 RA-PA 14.0 Thrombus
7 F TA IIc, CoA CoA resection, PAB 9.9 RA-PA 19.0
8 M DILV, L-MGA, PA Shunt 1.8 RA-PA 12.2 Thrombus
9 M DILV, MGA, PS Shunt 23.1 RA-PA 40.8
10 M DILV, L-MGA PAB 8.0 RA-PA 22.5
11 M DILV, L-MGA PAB 6.7 RA-PA 14.5
12 M DILV, PS, 2 × shunt 18.9 RA-PA 28.9
straddling AV valve
13 F TA IIb, PS 13.9 RA-PA 22.4 Thrombus
14 F DORV; left AV valve atresia, Valvotomy PV 5.5 RA-PA 17.4
PS, LPSVC, hemiazygos 
continuity
15 F DILV, left AV valve atresia, Shunt 10.3 RA-PA 23.9 Thrombus
L-MGA, PS
16 F DILV, MGA, CA, azygos PAB 14.3 RA-PA 24.2
continuity, subvalvular AS
17 M DILV, PS Shunt 13.2 RA-PA 20.3
18 M MA, LV hypoplasia, VSD PAB, ASE 4.9 RA-PA 15.4
19 F TA IIc 2× shunt 8.2 RA-PA, DKS 14.7 Thrombus
20 M Tricuspid stenosis, PS, VSD, VSD closure 6.5 RA-RV 18.4
ASD
21 M DILV 2 × PAB 19.4 RA-RV 26.9 Thrombus
22 M TA Ib Valvotomy PV, shunt 5.3 RA-RV 21.6
23 M TA Ib VSD enlargement 2.1 RA-RV 13.9
24 M TA, PS, ASD 6.7 RA-RV 19.3 Thrombus
25 M Hypoplastic RV, TV, VSD, PS Shunt 9.7 RA-RV 21.8
26 F TA Ib, PS Shunt 4.2 RA-RV 18.1 Thrombus
27 F TA Ib, PS 3.6 RA-RV 17.3
28 M TA Ib, PS 16.4 RA-RV 20.7 Thrombus
29 M TA Ib, restrictive VSD, RVOT patch, 1.0 RA-RV 11.1
RVOT obstruction VSD enlargement
30 F TA Ic PAB 5.9 RA-RV 19.6 Thrombus
intracardiac or extracardiac location with a visible basis to a
heart structure. The mass had to be seen in at least two dif-
ferent orthogonal planes. Furthermore, ventricular and atrio-
ventricular valve function, eventual right-to-left shunt at the
atrial level, and spontaneous echocardiographic contrast,
which is regarded as a marker for stagnant blood flow, were
documented. The ventricular function was classified as good,
fair, or poor, and aortic and atrioventricular valve regurgita-
tion was classified as absent, mild, moderate, or severe.
Cardiac catheterization was performed in 43 patients. The
exclusion criterion for catheterization was newly diagnosed
thrombus formation. A minimum of a 3-month interval of
oral anticoagulation therapy was regarded to be sufficient to
avoid potential complications provoked by a thrombus during
atrial catheterization. The study included measurement of
pressures and oxygen saturations within the superior and
inferior caval veins, the right and left atria, the pulmonary
artery system on the ventricular level, and the aorta. Cardiac
output was calculated by the Fick method with measured
oxygen consumption values. Biplane angiocardiograms of
the systemic veins, the right atrium, the pulmonary artery, the
ventricle, and the aorta were obtained.
Analysis of data. For statistical analysis, the measured val-
ues are reported as means ± SD, median, and range when
appropriate. Patients were grouped by the presence or
absence of an atrial thrombus. Data was compared by com-
puter-assisted analysis (StatView; Abacus Concepts, Inc,
Berkeley, Calif) by using the Mann-Whitney U test or con-
tingency tables (the Fisher exact P test).
Results
The age of the patients at the definitive Fontan proce-
dure varied between 1.0 and 24.1 years (mean, 9.3 ± 5.6
years; median, 7.2 years). The patients’ ages at investi-
gation ranged between 1.7 and 40.8 years (mean, 19.3 ±
7.4 years; median, 18.7 years). The mean interval
between Fontan operation and our study ranged from 0.7
to 18.4 years (mean, 9.9 ± 4.5 years; median, 10.0
years).
According to the functional status for congenital
heart disease,7 27 patients were in class I, 17 in class II,
6 in class III, and 2 in class IV. No significant differ-
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Table I. Continued
Patient Operation Age at Fontan Fontan Age at 
No. Sex Diagnosis before Fontan operation modification TEE Thrombus 
31 M TA Ib, PS 3 × shunt 7.2 RA-RV 24.4
32 F TA Ib, PS Shunt 15.6 RA-RV 32.4 Thrombus
33 F TA Ic PAB 13.7 RA-RV 22.3
34 M TA Ib, PS 3.2 RA-RV 16.8 Thrombus
35 F TA Ib, PS 6.0 RA-RV 21.5
36 M TA Ic PAB, ASE 5.7 RA-RV 14.7
37 M DILV, PS 3 × shunt, PCPC 9.5 TCPC fenestrated 10.2
38 F DILV 3 × shunt, PCPC 16.9 TCPC fenestrated 24.1
39 F TA Ib, PS 2 × shunt, Fontan 15.0 TCPC fenestrated 25.1
40 M DILV, single AV valve, MGA PAPVC 1.0 TCPC fenestrated 1.7
41 F TA Ib, PS Shunt, Fontan 19.7 TCPC fenestrated, MVR 38.1
42 F DILV, MGA, restrictive VSD ASE, PAB, PCPC, 4.8 TCPC, DKS 6.7
VSD enlargement
43 M DILV, subaortic RVOT, MGA 2 × PAB, 6.6 TCPC, nonfenstrated 10.5 Thrombus
VSD enlargement DKS
44 M DORV, hypoplastic AV 6.0 RA-PA 15.9
valve + LV, PS
45 M DILV, MGA, PS Shunt 4.4 RA-PA 13.5 Thrombus
46 F MV, hypoplastic LV, MGA, PS ASE 3.2 RA-PA 15.0
47 M DILV, MGA, PS PAB, CoA resection, 18.1 TCPC fenestrated 22.4
PCPC
48 F TA Ib, PS PAB, PCPC 4.4 RA-PA 13.4
49 M DORV, hypoplastic AV valve Shunt 5.5 TCPC fenstrated 6.4
+ LV, PS
50 M TA Ib, PS 23.6 RA-PA 36.0
51 F TA Ib, PS Shunt 10.6 RA-RV 21.1
52 M DILV, PA, dextrocardia 2 × shunt 8.1 RA-PA 21.7
MV, Mitral valve atresia; CA, common atrium; MGA, malposition of the great arteries (L-MGA, levo-malposition); DILV, double-inlet left ventricle; PS, valvular
and/or subvalvular pulmonary stenosis; TA, triscupid atresia (classification: Edwards and Burchell, 1949); PA, pulmonary atresia; LPA, left pulmonary artery; CoA,
coarctation of the aorta; DORV, double-outlet right ventricle; LPSVC, left persistent, superior vena cava; AV, atrioventricular; AS, aortic stenosis; TV, tricuspid valve;
RVOT, right ventricular outflow tract; LV, hypoplastic left ventricle; PAB, pulmonary artery banding; PV, pulmonary valve; ASE, atrial septectomy (Blalock-Hanlon
septectomy); VSD, ventricular septal defect; PCPC, partial cavopulmonary connection; PAPVC, partial anomalous pulmonary venous connection; RA-RV, right atri-
um–right ventricle; RA-PA, right atrium–pulmonary artery; DKS, Damus-Kaye-Stansel; TCPC, total cavopulmonary connection; MVR, mitral valve replacement.
ences could be shown between the functional status of
the patients with or without intracardiac thrombus for-
mation (11 in class I and 6 in class II).
Five (12%) patients had refractory protein-losing
enteropathy, and another 4 patients had a history of
recurrent effusions or ascites but normal serum albumin
and α1-antitrypsin levels.
These findings and others, such as sex, type of under-
lying heart disease, age at first Fontan operation, type
of Fontan modification, follow-up interval, presence of
cyanosis, or cardiac index, were not significantly dif-
ferent between the patients with or without intracardiac
thrombi (Table II).
Anticongestive medication (angiotensin-converting
enzyme inhibitors, glycosides, and diuretics) was given
to 38 patients, 26 of whom were additionally receiving
antiarrhythmic therapy. Fourteen patients did not take
any antiarrhythmic or anticongestive medication.
Before the investigation, 7 patients were receiving anti-
coagulation therapy because of an unfavorable hemo-
dynamic condition. In 2 of them, a thrombus formation
could be detected by TEE despite prophylactic antico-
agulation with phenprocoumon (INR 2.0-2.5) for 0.8 to
1.8 years before thrombus detection.
The standard electrocardiographic recordings
showed sinus rhythm in 30 patients, intermittent atrial
tachycardia in 18 patients, and permanent atrial
arrhythmia in another 3 patients. One had an atrioven-
tricular universal pacemaker implanted. A history of
significant atrial arrhythmia, documented by 24-hour
ambulatory monitoring, was present in 26 patients dur-
ing the last 12 months. In 9 of these 26 patients a
thrombus formation could be detected, but no statisti-
cally significant difference between patients with or
without arrhythmias could be found.
Laboratory findings of all patients are listed in Table
III, and catheterization data were available in 43
patients (Table IV). There was no statistically signifi-
cant difference in pressure and calculated parameters
between the patients with or without intracardiac
thrombus.
TEE identified thrombus formation in 17 (33%) of
52 patients. All thrombi were detected within the
right atrium, and only one was additionally found in
the left atrium close to the mitral valve. In 5 cases the
thrombus was localized at the superior part of the
posterior wall of the right atrium close to the superi-
or caval vein. Thrombi were located at the inferior
part of the posterior wall in 4 cases, and 4 thrombi
were covering the complete posterior wall. Another 3
thrombi were adherent to the lateral part and a fourth
to the anterior wall.





thrombus formation P values
No. of patients (n = 52) 35 17
Sex (F/M) 14/21 10/7 .2
Age at Fontan 9.7 ± 5.9 8.6 ± 5.0 .5
operation (y)
TEE follow-up (y) 19.6 ± 8.3 18.6 ± 5.5 .6
Diagnostic group 13/15/3/4 8/8/1/0 .5
(DILV/TA/MA/others)
Operation group 16/10/9 8/8/1 .14
(RA-PA/RA-RV/TCPC)
PLE 5 0 .15
Recurrent effussions 2 2 .6
(no PLE)
History of stroke 3 0 .5
Arrythmias 17 9 .99
DILV, Double-inlet left ventricle; TA, triscupid atresia; MA, mitral atresia; RA-
PA, right atrium–pulmonary artery anastomosis; RA-RV, right atrium–right
ventricle anastomosis; TCPC, total cavopulmonary anastomosis; PLE, pro-
tein-losing enteropathy.
Table III. Laboratory findings
No Thrombus 
thrombus formation P values
No. of patients (n = 52) 35 17
Hematocrit level (V/V) 0.47 ± 0.05 0.46 ± 0.05 .7
Albumin (%) 54.4 ± 6.4 55.6 ± 3.8 .5
PTT (%) 83.0 ± 22.6 76.0 ± 16.3 .3
Antithrombin III (%) 90.2 ± 11.1 91.4 ± 11.7 .7
Protein C (%) 85.7 ± 25.5 91.7 ± 22.2 .5
Protein S (%) 91.6 ± 7.6 90.9 ± 11.6 .8
V/V, Volume fraction (volume red cells/volume whole blood); PTT, partial
thromboplastin time.
Table IV. Hemodynamic data
No Thrombus 
thrombus formation P values
No. of patients (n = 43) 31 12
RA mean pressure 12.8 ± 3.5 11.8 ± 2.8 .4
(mm Hg)
PA-LA gradient (mm Hg) 4.1 ± 2.3 3.9 ± 2.4 .8
PA mean pressure 11.9 ± 3.8 11.9 ± 4.8 .98
(mm Hg)
LV end-diastolic pressure 8.4 ± 4.0 7.6 ± 2.4 .5
(mm Hg)
Arterial SO2 (%) 92.8 ± 4.2 93.9 ± 3.7 .5
Qp (L · min–1 · m–2 BSA) 2.6 ± 0.6 3.1 ± 1.3 .06
Q
s
(L · min–1 · m–2 BSA) 2.8 ± 0.9 2.9 ± 0.8 .7
Rp (U × m2 BSA) 1.8 ± 1.2 1.4 ± 0.9 .2
RS (U × m2 BSA) 23.6 ± 9.8 22.9 ± 9.8 .8
Cardiac index 2.4 ± 0.6 2.4 ± 0.6 .8
(L · min–1 · m–2 BSA)
RA, Right atrium; PA, pulmonary artery; LA, left atrium; LV, left ventricle;
SO2, oxygen saturation; Qp, pulmonary flow; BSA, body surface area; Qs, sys-
temic flow; Rp, pulmonary resistance; U, Wood units; RS, systemic resistance.
By using TEE, spontaneous contrast in the right atri-
um or within the Fontan connection was documented in
34 (65%) patients. The occurrence of spontaneous
microcavitations in the atrium did not differ signifi-
cantly between patients with or without thrombus for-
mation. Furthermore, no significant difference was
found between the two groups regarding atrioventricu-
lar function and ventricular function (Table V).
A thrombus formation within the right atrium could
be suspected by use of transthoracic echocardiography
before TEE in only 1 patient. The remaining 16 cases
could be visualized only by means of TEE.
Discussion
Thrombi are an important complication after a
Fontan operation. The true incidence of central venous
intracardiac thrombosis and subclinical occurrence of
arterial embolization is certainly unknown and often
underestimated in patients having undergone a Fontan
operation. In a study of cerebrovascular accidents after
a Fontan operation, du Plessis and coworkers8
described a stroke incidence of 2.6% among 645
patients over a 15-year period.
In our series of 52 patients after Fontan-type opera-
tions, we found a high occurrence rate (33%) of intra-
cardiac thrombi. In all but one patient transthoracic
echocardiography before TEE was unable to identify a
thrombus. All thrombi were detected within the right
atrium, and only one was additionally found in the left
atrium close to the mitral valve. Location of intracar-
diac thrombi may also occur in the systemic ventricle,
rudimentary ventricle, pulmonary artery, or pulmonary
artery stump after its distal ligation,9-12 but not in our
study so far.
The symptoms of thrombus formation include
venous obstruction, progressive cyanosis, paradoxic
emboli to the cerebral or peripheral circulation (if
right-to-left atrial shunt is present), or atrial tachy-
arrhythmia.13-15 One of our patients had a history of
pulmonary embolization, and 3 others had a history of
systemic or cerebrovascular embolization. The source
of thromboembolism remained unknown, but cardiac
anatomy was not investigated by TEE at that time.
None of our patients had acute clinical signs of throm-
boembolic events at the time of investigation, which
was mandatory for inclusion into the study. In a retro-
spective study, Rosenthal and coworkers9 reported that
approximately 43% of the patients with thrombi were
asymptomatic. However, 21% of the patients in whom
a thrombus formation was previously demonstrated
died of a thromboembolic event.
Predisposing risk factors for the development of
thrombi and subsequent embolization are a slow and
nonpulsatile flow through the caval veins; a poorly con-
tracting, enlarged, and thickened atrium with or with-
out arrhythmias; a small transpulmonary gradient that
decreases flow within the tunnel; a low cardiac output
with or without atrioventricular valve regurgitation; or
an obstructed conduit or a complex baffling because of
unusual venous return.16
The overall reported incidence of intracardiac throm-
bus formation after the Fontan operation identified by
TEE ranges has been shown to be between 6% and
44%,17-21 but the number of the investigated patients
was small and selected for various problems (n = 9-30
patients, Table VI). Despite this, TEE is rarely used for
postoperative follow-up.
Our study confirms the high occurrence of intracar-
diac thrombi (33% in 52 patients), but we were unable
to define specific previous surgical management as a
risk factor for thrombosis.9,11 The frequency of throm-
bosis was similar after total cavopulmonary, atrio-
pulmonary, or atral–right ventricular connections.
However, we mainly studied older patients with a long
follow-up period (>10 years). The number of patients
with TCPC was too small in comparison with those
with the classic atriopulmonary or atrial–right ventric-
ular connection to predict the occurrence rate of throm-
bosis in patients with that type of modification, which
is more commonly used today.
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Table V. Echocardiographic findings
No Thrombus 
thrombus formation P values
No. of patients (n = 52) 35 17
Spontaneous contrast 23 11 .99
SV function 17/6/6/6 9/3/4/1 .7
(normal/fair/reduced/poor)
AV valve regurgitation 7/23/4/0 5/12/0/1 .4
(no/mild/moderate/severe)
SV, Single ventricle; AV, atrioventricular.
Table VI. Reports with TEE to assess occurrence rate
of intracardiac thrombi in patients after Fontan oper-
ations
No. of No. of patients 
Authors patients with thrombus 95% CI
Stümper and colleagues, 18 3 (17%) 3.6–41.4
199116
Fyfe and colleagues, 199117 30 6 (20%) 7.7–38.6
Feltes and colleagues 1994,18 9 4 (44%) 13.7–78.8
Shirai and colleagues, 199819 16 3 (19%) 4.1–45.7
Presented study 52 17 (33%) 20.3–41.1
CI, Confidence interval.
There is a substantial incidence of early and late
arrhythmias after the various modifications of the
Fontan procedure.22,23 Parallel to previous TEE stud-
ies,18,19 we could not show any consistency between
thrombus formation and arrhythmias or the type of
Fontan modification.
Abnormalities of the clotting system, mainly protein
C or protein S deficiency, reduced concentration of
antithrombin III, and elevated activity of the von
Willebrand factor may additionally be involved in pro-
thrombotic reactions in patients having undergone a
Fontan operation,3,15,20 although it failed in this study
to be a prognostic risk factor. This was because the
number of patients with clotting abnormalities was not
significantly different in the groups with and without
intracardiac thrombi.
Specific hemodynamic data, such as blood flow, sat-
uration, atrial pressure, and pulmonary resistance or
obstructions, did not differ significantly in patients with
or without thrombus formation.
In a literature review of children having undergone a
Fontan-type operation, Michelson and coworkers24
found 26 publications dealing with 486 patients. Only
3 of the included publications reported the use of
antithrombotic therapy.
Today the role of long-term anticoagulation with
warfarin remains controversial. No consensus is found
in the literature or routine clinical practice about the
optimal type or duration of anticoagulation.6 Pre-
dominantly, patients with low cardiac output, with or
without residual right-to-left shunting, are thought to
benefit from anticoagulation.
At most cardiac centers, a wide variety of prophylac-
tic anticoagulation regimens exists, ranging from no
antiplatelet therapy in asymptomatic patients up to a
life-long regimen of anticoagulation therapy with war-
farin in all patients having undergone a Fontan opera-
tion.9,11,15,25 Virtually no information regarding the
safety and efficacy or the duration of prophylactic oral
anticoagulation therapy exists. Because randomized,
controlled, prospective trials are not available, statisti-
cally based guidelines for the management of children
and adolescents after Fontan-like operations do not
exist.6
The use of anticoagulant therapy has always been
weighed against the risk of hemorrhagic complications.
Rosenthal and coworkers9 estimated an approximately
constant hazard rate of 3.9 bleeding events per 100
patient-years. Apart from the therapeutic aspects, a
“good Fontan adolescent” will struggle against any med-
ication that distances him or her further from normality
to maintain his or her self-esteem and will tend to neglect
his or her medical history and current problems.2
At our institution, we keep the INR target levels in
patients after a modified Fontan operation between 3.0
and 4.5. The recommendations for an appropriate INR
for children may be lower than that found in
adults,24,26,27 but the optimal INR to prevent thrombus
formation in children having undergone a Fontan oper-
ation remains unclear, and recommendations are usual-
ly defined according to the experience with patients
after prosthetic valve operations.
Of the 7 patients who were receiving oral anticoagu-
lation therapy, 2 were shown to have an intracardiac
thrombus formation. At the time of our study, one of
these patients had an INR of 2.5, and the other had an
INR of 2.0. Both were symptom-free. An additional
anticoagulation disorder could not be diagnosed in
these patients.
Jahangiri and colleagues11 described one patient with
left-sided hemiparesis after administration of warfarin
(INR 2.8), and a similar case was reported by Danielson
in his comment. The incidence of venous thrombosis
despite prophylactic oral anticoagulation with warfarin,
as published by Jonas10 in 1995, was 7.4%.
Conclusion
Intracardiac thrombi and consecutive thromboem-
bolism can cause significant morbidity and mortality
after a modified Fontan operation. This study found a
high occurrence of intracardiac thrombi in asympto-
matic patients. Although thrombus detection by
transthoracic techniques is insufficient, TEE has
proven to be the method of choice because it provides
an excellent view of the atrial structures and central
venous connections.
The incidence of thrombosis despite oral anticoagu-
lation remains unknown. We were unable to define
anatomic, laboratory, or hemodynamic risk factors.
Thrombus formation seems to be unpredictable in the
postoperative course. The preliminary data of this
study may justify the recommendation of oral antico-
agulation prophylaxis in patients having undergone a
Fontan operation. The outcome of clinical studies with
a controlled, prospective, randomized design should
allow us to conclude whether life-long prophylaxis is
indicated and to determine the optimal INR target level.
For all patients without anticoagulation medication or
inadequate INRs, we would suggest a TEE screening
for thrombosis.
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Commentary
The article by Balling and associates addresses the
very important issue of intracardiac thrombus forma-
tion and its possible prevention by routine anticoagula-
tion in patients after the Fontan procedure. Thrombo-
embolic stroke in a child is a devastating complication
that often has lifelong consequences for the child and
family. Furthermore, evidence is steadily accumulating
that there is indeed a procoagulant state with Fontan
physiology. For example, recent work by Jahangiri and
associates, both in London and in Boston, has demon-
strated a decreased level of protein C and protein S, as
well as an increase in some procoagulant factors.
Balling and associates reviewed the case histories of
52 patients late after a Fontan procedure. All patients
had undergone transesophageal echocardiographic
(TEE) studies as part of a program intended to identify
the incidence of thrombus in these patients, although it
appears that much of the non-TEE patient-related data
were not collected prospectively, but through a retro-
spective chart review. They identified a remarkably
high incidence of intra-atrial thrombi (almost all in the
right atrium), although not inconsistent with previous
reports. They conclude that routine TEE is probably
justified for patients after the Fontan procedure and that
routine anticoagulation is probably advisable.
Before accepting the recommendations of Balling
and associates, it is important to recognize some sig-
nificant limitations of their report. As noted above, this
is effectively a retrospective review of a selected group
of patients who agreed to the TEE procedure. Most
patients had undergone their Fontan operation many
years before, and therefore only 9 of the 52 had had lat-
eral tunnel–type Fontan procedures. Most had had the
old-style right atrium–pulmonary artery anastomosis.
Only 7 had a fenestration. Interestingly, none of the
patients with a fenestration had detectable thrombus.
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None of the patients had had a recent thromboembolic
event that was symptomatic, and of the 3 patients who
had had cerebrovascular events in the past, none had
identifiable thrombus by TEE.
With respect to the recommendation regarding anti-
coagulation, it is important to note that thrombi devel-
oped in 7 of these patients despite warfarin sodium
(Coumadin) anticoagulation, although the authors
would argue that some of these patients at least did not
have adequate anticoagulation. The risks of anticoagu-
lation need to be balanced against the morbidity of
asymptomatic thrombi detected by routine screening.
The risks of routine screening also need to be carefully
considered when one notes that nearly 50% of this pop-
ulation required general anesthesia to undergo the TEE
procedure.
The technique of TEE is probably quite sensitive to
detect intra-atrial thrombi, but the authors have not
addressed the specificity of the method. They are now
embarking on a study in which magnetic resonance
imaging will be used to exclude false positive results,
but until the results of that investigation and others
are available, it is hard to support the aggressive rec-
ommendation for routine TEE and routine anticoagu-
lation in this difficult patient population. Never-
theless, a provocative report such as this article by
Balling and associates does highlight the importance
once again of urgently completing at least one (and
ideally more than one) carefully organized prospec-
tive randomized study to address the issue of war-
farin sodium versus aspirin versus no anticoagulation
in patients after the Fontan procedure. It is important
that such studies have sensitive and specific methods
for intracardiac thrombus formation, as well as care-
ful prospective assessment for symptoms and signs of
thromboembolic events.
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